Results 51 to 60 of about 28,496 (220)

Circulating monocyte partitioning and its alteration in hematological chronic neoplasms

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Circulating monocyte partitioning refers to the relative quantification of the three main monocyte subsets in the peripheral blood, namely classical (cMo), intermediate (iMo), and non‐classical (ncMo) monocytes, as assessed by flow cytometry, a new nomenclature described 15 years ago.
Sihem Tarfi, Dorothée Selimoglu‐Buet, Ivan Sloma, Orianne Wagner‐Ballon, on behalf of the French group CytHem‐LMMC   +4 more
wiley   +1 more source

Advanced Lung Cancer Inflammation Index as a Prognostic Inflammation–Nutrition Marker in Appendiceal High‐Grade Pseudomyxoma Peritonei: A 10‐Year Single‐Center Study

ANZ Journal of Surgery, EarlyView.
Among 223 patients with appendiceal high‐grade pseudomyxoma peritonei, a high advanced lung cancer inflammation index (ALI) was independently associated with improved overall survival. A nomogram integrating ALI with clinicopathological and surgical factors showed good discrimination, calibration, and clinical utility for predicting 1‐, 2‐, and 3‐year ...
Yun Gao, Ruiqing Ma, Zhenhai Feng, Siyi Yang, Guangyu An   +4 more
wiley   +1 more source

Single-cell analysis based dissection of clonality in myelofibrosis

Nature Communications, 2020
Myelofibrosis is a myeloproliferative neoplasm. Here, the authors show the clonal evolution of myelofibrosis during JAK inhibitor therapy, revealing how the treatment results in an increase in clonal complexity and a gain of RAS pathway mutations.
Elena Mylonas, Kenichi Yoshida, Mareike Frick, Kaja Hoyer, Friederike Christen, Jaspal Kaeda, Matthias Obenaus, Daniel Noerenberg, Cornelius Hennch, Willy Chan, Yotaro Ochi, Yuichi Shiraishi, Yusuke Shiozawa, Thorsten Zenz, Christopher C. Oakes, Birgit Sawitzki, Michaela Schwarz, Lars Bullinger, Philipp le Coutre, Matthew J. J. Rose-Zerilli, Seishi Ogawa, Frederik Damm   +21 more
doaj   +1 more source

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

British Journal of Haematology, EarlyView.
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Trinayan Kashyap, Andrea A. Ellero, Christopher J. Walker, Marie E. Maloof, Min Lu, Lijuan Xia, Ronald Hoffman, Pietro Taverna   +7 more
wiley   +1 more source

Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms

Haematologica, 2017
High mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is negatively regulated by let-7 microRNA through binding to it’s 3′-untranslated region. Transgenic mice expressing Hmga2 with a truncation of its 3′-untranslated region
Chih-Cheng Chen, Jie-Yu You, Jrhau Lung, Cih-En Huang, Yi-Yang Chen, Yu-Wei Leu, Hsing-Ying Ho, Chian-Pei Li, Chang-Hsien Lu, Kuan-Der Lee, Chia-Chen Hsu, Jyh-Pyng Gau   +11 more
doaj   +1 more source

Acute liver failure precipitated by acute Budd‐Chiari syndrome and complete portal vein thrombosis

Clinical Case Reports, 2021
Acute Budd‐Chiari syndrome and complete portal vein thrombosis are important features of myeloproliferative neoplasm that may occur simultaneously, resulting in acute liver failure.
Yuji Suzuki, Akiko Suzuki, Keisuke Kakisaka, Yasuhiro Takikawa   +3 more
doaj   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Arterial and Venous Thrombosis in Patients with Myeloproliferative Neoplasms

Jurnal Penyakit Dalam Indonesia, 2019
Introduction. Myeloproliferative neoplasm (MPN) is a hematologic disorder that consists of polycythemia vera (PV), essential thrombocythemia (ET and primary myelofibrosis (PMF) and complication of thrombosis is frequently found in patients with MPN. This
Lugyanti Sukrisman
doaj   +1 more source

Mosaic chromosomal alterations and relation to haematological cancer in two large Danish cohorts

British Journal of Haematology, EarlyView.
Summary Mosaic chromosomal alterations (mCAs) are large somatic gains, losses and copy‐neutral loss of heterozygosity identified in the peripheral blood, which represent a relatively unexplored spectrum of clonal haematopoiesis. We aimed to describe mCAs in two large Danish cohorts with extensive long‐term registry‐based follow‐up and examine ...
Cecilie Velsoe Maeng, Pei Meng, Mathias Heldbo, Olafur Davidsson, Morten Munk Johansen, Sigrún Thorsteinsdóttir, Jojo Biel‐Nielsen Dietz, Ragnar Pétur Kristjansson, Ole Birger Vesterager Pedersen, Erik Sørensen, Christian Erikstrup, Christina Mikkelsen, Nanna Brøns, Henrik Ullum, Bitten Aagaard, Mie Topholm Bruun, Estrid Høgdall, DBDS Research Consortium, CHB Research Consortium, Bo Porse, Simon Husby, Sisse R. Ostrowski, Henrik Hjalgrim, Kirsten Grønbæk   +23 more
wiley   +1 more source

Hyperglycaemia as a predictor of morbidity and mortality in patients receiving an allogeneic haematopoietic stem cell transplantation

British Journal of Haematology, EarlyView.
Summary Allogeneic haematopoietic stem cell transplantation (allo‐HSCT) is an effective treatment for patients with haematological malignancies; however, post‐transplant complications, including infections and acute graft‐versus‐host disease (aGvHD), remain significant issues. Identifying modifiable risk factors is therefore critical to improve patient
Marieke Tienstra, Fleur R. Goemans, Kylie Keijzer, Inge V. G. Oteman, Carin L. E. Hazenberg, Jaap A. van Doesum, Anne G. H. Niezink, Goda Choi, Gerwin A. Huls, Peter R. van Dijk, Hilde A. M. Kooistra, Tom van Meerten, Linde M. Morsink   +12 more
wiley   +1 more source